Enveric Biosciences Inc (NASDAQ: ENVB) shares climbed 13.63%, or $0.024 per share, as on 11:54:32 est today. Since opening the day at $0.18, 1,521,638 shares of Enveric exchanged hands and the stock has moved between $0.20 and $0.18.  

This year the company has a YTD change of 81.06%.

Enveric is set to release earnings on 2022-05-16.

For technical charts, analysis, and more on Enveric visit the company profile.

About Enveric Biosciences Inc

Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy.

To get more information on Enveric Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Enveric Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast

Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement

Target Hits 52-Week Low After Missing Badly on First Quarter Earnings

DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter

Another Crypto Winter Wipes Out Billions in Market Value

Inflation + Recession = Recipe for Volatility